Lung Cancer
Page 1 • 2 itemsGain critical insights into global lung cancer drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
FDA Accelerated Approval of KRAS G12C Inhibitors in NSCLC: Sotorasib vs Adagrasib
This article delves into the FDA's accelerated approval of KRAS G12C inhibitors, Sotorasib and Adagrasib, highlighting their impact on NSCLC treatment.
Boehringer Ingelheim's Zongertinib Shows Promise for HER2-Mutant Lung Cancer in NEJM Study
Boehringer Ingelheim's zongertinib demonstrates efficacy in HER2-mutant NSCLC patients, with Phase 1b Beamion LUNG-1 results published in NEJM following FDA approval.